9 Sources of evidence considered by the Committee

9 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Warwick Evidence:

  • Connock M, Cummins E, Sutcliffe P et al. Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (June 2011)

The NICE Decision Support Unit (DSU) report for this appraisal:

  • Tappenden P, Wailoo A, Stevens J et al. Eliciting estimates of long‑term treatment discontinuation rates (June 2013)

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • GlaxoSmithKline

II. Professional/expert and patient/carer groups:

  • Lupus UK

  • National Kidney Federation

  • British Association of Dermatologists

  • British Health Professionals In Rheumatology

  • British Renal Society

  • British Society for Rheumatology

  • Primary Care Rheumatology Society

  • Renal Association

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

III. Other consultees:

  • Bolton Primary Care Trust

  • Department of Health

  • NHS England

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety, Northern Ireland

  • Healthcare Improvement Scotland

  • Arthritis Research UK

  • Cochrane Skin Group

  • Kidney Research UK

  • National Institute for Health Research Health Technology Assessment Programme

  • Warwick Evidence

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on belimumab by attending the initial committee discussion and providing written evidence to the committee. They were invited to comment on the ACD.

  • Professor David Isenberg, Academic Director of Rheumatology, University College London, nominated by British Society for Rheumatology – clinical expert.

  • Dr Liz Lightstone, Consultant Renal Physician, nominated by Renal Association – clinical expert.

  • Jane Dunnage, Chair and Trustee of Lupus UK, nominated by Lupus UK – patient expert.

  • Chris Maker, Director of Lupus UK, nominated by Lupus UK – patient expert.

D. The following individuals were nominated as NHS commissioning experts by the selected PCT allocated to this appraisal. They gave their expert/NHS commissioning personal view on belimumab by attending the initial committee discussion and providing written evidence to the committee. They were invited to comment on the ACD.

  • Johanna Taylor, Clinical Effectiveness Pharmacist, Bolton Primary Care Trust, selected by Bolton Primary Care Trust – NHS Commissioning.

E. Representatives from the following company attended committee meetings. They contributed only when asked by the committee chair to clarify specific issues and comment on factual accuracy.

  • GlaxoSmithKline

  • National Institute for Health and Care Excellence (NICE)